Treatment Outcome of the Combination Therapy of High-dose rate Intracavitary Brachytherapy and Intensity-modulated Radiation Therapy With Central-shielding for Cervical Cancer
| Autor: | Ryosuke Shirata, Hideyuki Hongo, Akiko Sato, Kengo Matsui, Y. Mukai, Yumiko Minagawa, Masaharu Hata, Tomio Inoue, Harumitu Hashimoto, Motoko Omura, Takanori Fukuda, Kazuya Onuma, Hironori Nagata, Hiromi Inoue |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
Combination therapy medicine.medical_treatment Brachytherapy Treatment outcome Uterine Cervical Neoplasms General Biochemistry Genetics and Molecular Biology Tomotherapy medicine Humans Retrospective Studies Pharmacology Cervical cancer business.industry Intracavitary brachytherapy Radiotherapy Dosage Intensity-modulated radiation therapy medicine.disease Radiation therapy Treatment Outcome Female Radiotherapy Intensity-Modulated Dose rate business Nuclear medicine Research Article |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 0258-851X |
| Popis: | Background/aim This study aimed to evaluate the clinical outcome of intensity-modulated radiation therapy (IMRT) and high-dose-rate intracavitary brachytherapy (HDR-ICBT) in uterine cervical cancer (UCC). IMRT consisted of whole-pelvic radiation therapy (WPRT) and sequential WPRT with central-shielding (WPRT-CS). Patients and methods Thirty UCC patients treated with IMRT using TomoTherapy, were retrospectively analyzed. Results The median dose of WPRT and WPRT-CS was 36 and 14.4 Gy and the median total dose of these was 50 Gy in 25 fractions (Fr). Median HDR-ICBT dose/Fr to Point A was 25 Gy/5 Fr. Median 2 Gy per fraction-equivalent dose (EQD2) of combined WPRT and HDR-ICBT to Point A (α/β=10) was 71.0 Gy. The 3-year local control, disease-free survival, and overall survival rates were 89.9%, 83.3%, and 86.3%. Conclusion IMRT of WPRT and WPRT-CS given in combination with HDR-ICBT was a feasible therapy resulting in good disease control and tolerance in patients with UCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|